ORIGINAL RESEARCH
Oncology
doi: 10.25005/2074-0581-2026-28-1-76-87
EVALUATION OF THE EFFICIENCY OF COMBINED TREATMENT OF PATIENTS WITH BONE METASTASES FROM KIDNEY AND PROSTATE CANCER USING SYSTEMIC RADIATION AND TARGETED THERAPY

N.M. RAKHIMOV, SH.SH. SHAKHANOVA

Department of Oncology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan

Objective: To improve the effectiveness of treatment for multiple osteogenic metastases from kidney and prostate cancer by optimizing the combined use of systemic radiation therapy and osteomodifying agents.

Methods: This study, conducted at the Department of Oncology, Samarkand State Medical University, Samarkand, Uzbekistan, analyzed observational data from 110 patients with morphologically verified malignant neoplasms of the urinary system and multiple osteogenic metastases. Patients were divided into three groups. Outcomes were evaluated using bone pain dynamics scales, the WHO analgesic scale, and the Karnofsky performance status.

Results: Subjective pain reduction and improved general condition were observed in 56 (87.5%) patients. A decrease in analgesic frequency and dosage occurred in 50 (78.1%) patients, with 14 (21.8%) discontinuing analgesics entirely. Improved mobility was reported by 29 (45.3%) patients, while 35 (54.6%) reported regaining full mobility. The combination of bisphosphonates, Denosumab, and Samarium (153Sm) lexidronam (Oxabifor) increased three-year survival by 32.3% and five-year survival by 15.0%

Conclusion: A new protocol for multiple osteogenic metastases was tested, adding Oxabifor and Denosumab to standard therapy, with positive results. When bisphosphonates are contraindicated or ineffective, the combination of Denosumab and Oxabifor is the recommended treatment.

Keywords: Kidney cancer, prostate cancer, bone metastases, radiopharmaceutical therapy, systemic radiation therapy, Samarium (153Sm) lexidronam (Ox- abifor), Denosumab.

Download file:

References
  1. Anderson CM, Joshua AM, Kim DW. Clinical outcomes and patterns of care in patients with bone metastases from renal cell carcinoma: Results from a large multicenter study. Cancer Research. 2022;82(15):2789-801. https://doi. org/10.1158/0008-5472.CAN-21-3842
  2. Bianchi L, Rossi L, Tomao F, Papa A, Zoratto F, Tomao S. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocrine-Related Cancer. 2013;20:233-45. https://doi.org/10.1530/ERC-13-0201
  3. Diao W, Cai H, Chen L, Jin X, Liao X, Jia Z. Recent advances in prostate- specific membrane antigen-based radiopharmaceuticals. Curr Top Med Chem. 2019;19:33-56. https://doi.org/10.2174/1568026619666190201100739
  4. Parker C, Heinrich D, O’Sullivan JM, Fossa S, Chodacki A, Demkow T, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in Castration-resistant Prostate Cancer (CRPC): A phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011;47(Suppl. 2):3. https://doi.org/10.1056/NEJMoa1213755
  5. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019. Journal of the National Comprehensive Cancer Network. 2019;17(5):479-505. https://doi.org/10.6004/jnccn.2019.0023
  6. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536-44. https:// doi.org/10.1007/s00259-019-04485-3
  7. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. https://doi.org/10.1056/NEJMoa1213755
  8. Kaprin AD, Starinskiy VV, Shakhzadova AO. Sostoyanie onkologicheskoy pomosh- chi naseleniyu Rossii v 2021 godu [The state of oncological care for the popula- tion of Russia in 2021]. Moscow, RF: MNIOI im. P.A. Gertsena – filial FGBU «NMIC radiologii» Minzdrava Rossii; 2022. 239 p.
  9. Gameyeva EV, Stepanova AM, Tkachenko GA, Gridnev OV, Sviridov SV, Shestopalov AE. Kompleksnaya reabilitasiya onkologicheskikh patsientov [Comprehensive rehabilitation of cancer patients]. Sovremennaya onkologiya. 2022;24(1):90-6. https://doi.org/10.26442/18151434.2022.1.201476
  10. Mahmud RA, Alam K, Dunn J, Gow J. The changing relationship between health burden and work disability of Australian cancer survivors, 2003-2017: Evidence from a longitudinal survey. BMC Public Health. 2020;20(1):548. https://doi. org/10.1186/s12889-020-08710-9
  11. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9. https://doi.org/10.1200/JCO.2010.29.7101
  12. Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723-38. https://doi.org/10.1007/s00259-016- 3415-4
  13. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng Q, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration- resistant prostate cancer and bone metastases (ERA 223): A randomised, double- blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):408-19. https://doi.org/10.1016/S1470-2045(18)30860-X
  14. Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate- specific membrane antigen (PSMA) expression deemed ineligible for 177Lu- labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2(6):670-6. https://doi. org/10.1016/j.euo.2018.11.007
  15. Rossiyskoe obshchestvo klinicheskoy onkologii, Assotsiatsiya onkologov Rossii. Metastaticheskoe porazhenie kostey pri zlokachestvennykh novoobrazovani- yakh: klinicheskie rekomendatsii [Bone metastasis in malignant neoplasms: Clinical guidelines]. Moscow, RF: 2023. Vozrastnaya gruppa: vzroslye. Kody MKB: C79.5, M84.4, M90.7, M87.1, G95.2, E83.5.
  16. Mahajan S, Gavane S, Pandit-Taskar N. Targeted Radiopharmaceutical Therapy for Bone Metastases. Semin Nucl Med. 2024;54(4):497-512. https://doi. org/10.1053/j.semnuclmed.2024.05.006
  17. Thang SP, Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517-23. https://doi.org/10.2967/ jnumed.118.219352
  18. Yamamichi G, Kato T, Uemura M, Nonomura N. Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers. Anticancer Res. 2023;43(1):283-90. https://doi.org/10.21873/anticanres.16161

Authors' information:

Rakhimov Nodir Makhammatkulovich,
Doctor of Medical Sciences, Professor of the Department of Oncology, Samarkand State Medical University
Scopus ID: 58175052900
ORCID ID: 0000-0003-4618-0847
SPIN: 1115-1727
Author ID: 822646
E-mail: rahimovnodir280377@gmail.com

Shakhanova Shakhnoza Shavkatovna,
Candidate of Medical Sciences, Associate Professor of the Department of Oncology, Samarkand State Medical University
Researcher ID: GWV-1252-2022
ORCID ID: 0000-0003-0888-9150
SPIN: 9241-2431
Author ID: 1273417
E-mail: shaxnoza.medic@gmail.com

Information about support in the form of grants, equipment, medications

The author did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Shakhanova Shakhnoza Shavkatovna
Candidate of Medical Sciences, Associate Professor of the Department of On- cology, Samarkand State Medical University

140100, Republic of Uzbekistan, Samarkand, Amir Temur str., 18

Tel.: +998 (933) 534075

E-mail: shaxnoza.medic@gmail.com


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. INCIDENCE OF MULTIPLE PRIMARY MALIGNANT NEOPLASMS IN SIBERIA AND THE FAR EAST
  2. SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER: ONGOING CONSIDERATIONS
  3. ROLE OF RADIATION THERAPY IN COMBINED AND MULTIMODAL TREATMENT OF T3-4N1-2-3M0-1-2 STAGE SKIN CANCER
  4. SURGICAL TREATMENT OF A GIANT RETROPERITONEAL LIPOMA: A CLINICAL CASE
  5. PREOPERATIVE PREDICTION OF WALL INVASION DEPTH OF PRIMARY TUMOR (PT) IN GASTRIC CANCER PATIENTS
  6. CURRENT SURGICAL TREATMENT OPTIONS FOR LATE STAGES OF CERVICAL CANCER
  7. METASTATIC HEAD AND NECK CANCER WITH UNKNOWN PRIMARY: DIAGNOSIS AND TREATMENT
  8. CLINICAL CASE OF BCLC STAGE B HEPATOCELLULAR CARCINOMA WITH A COMBINED TREATMENT
  9. MODERN VIEW ON REHABILITATION OF CANCER PATIENTS
  10. COMPLEX DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA IN THE REPUBLIC OF TAJIKISTAN

◄ Back to the list